Business Context and Reporting Period
Company: PACS Group, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: PACS Group is a leading post-acute healthcare company operating 316 skilled nursing, assisted living, and independent living facilities across 17 states. As of June 30, 2025, the company operated 32,208 skilled nursing beds and 2,419 assisted living beds. The company's strategy focuses on acquiring underperforming facilities and transforming them into higher-acuity transitional care centers.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $1,309,236 | $2,586,386 |
| Net Income (Loss) | $50,966 | $79,346 |
| Net Income Attributable to PACS Group | $50,963 | $79,435 |
| Diluted EPS | $0.31 | $0.48 |
| Operating Cash Flow (6 months) | N/A | $202,818 |
| Cash and Cash Equivalents (Balance Sheet) | $294,173 | $294,173 |
| Total Debt (Current + Long-Term) | $257,138 | $257,138 |
| Line of Credit Outstanding | $142,000 | $142,000 |
Note: Total Debt includes $10,146 in current maturities and $246,992 in long-term debt (net of deferred financing fees).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 39.9% year-over-year for the three months ended June 30, 2025, and 39.4% for the six-month period. This growth was driven primarily by an increase in operational beds (up 31.6%) and patient days.
- Profitability Turnaround: The company reported a net income of $50.9 million for the quarter, compared to a net loss of $31.9 million in the same period in 2024. Operating income improved from a loss of $37.2 million to a profit of $80.5 million.
- Restatement of Prior Periods: The company restated financial results for the three and six months ended June 30, 2024. Adjustments included revenue reductions related to Medicare Part B billing and lease classification corrections (operating vs. finance leases), which significantly impacted prior period net income and balance sheet liabilities.
- Expense Management: General and administrative expenses decreased by 26.6% in the quarter, largely due to a reduction in stock-based compensation compared to the IPO-related grants in the prior year. However, legal and professional fees increased by $24.1 million due to ongoing investigations.
- Occupancy Rates: Overall occupancy decreased slightly to 88.6% (Q2 2025) from 91.0% (Q2 2024), driven by lower occupancy in "New" and "Ramping" facility cohorts, though "Mature" facilities saw an increase to 94.7%.
Guidance, Outlook, Risks, and Contingencies
- Credit Facility Forbearance: The company is currently in a forbearance agreement with its lenders regarding its Amended and Restated Credit Facility. This follows "Technical Events of Default" related to inaccuracies in representations and warranties and non-compliance with certain covenants. The forbearance period was extended through November 30, 2025. During this period, the company is prohibited from borrowing new loans and must maintain minimum liquidity of $100 million.
- Regulatory Investigations: The company is subject to multiple ongoing investigations:
- DOJ: Four separate Civil Investigative Demands (CIDs) and a subpoena regarding potential False Claims Act violations, Anti-Kickback Statute violations, and HIPAA issues related to Medicare billing, patient referrals, and COVID-19 waivers.
- SEC: An ongoing investigation into the company's accounting, financial reporting, disclosure, and internal controls.
- Legal Litigation: The company faces a consolidated securities class action lawsuit (Manchin v. PACS Group, Inc.) and multiple shareholder derivative actions alleging revenue inflation, billing fraud, and breach of fiduciary duties. No settlement ranges have been established.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in the control environment and revenue recognition processes. A remediation plan is underway, including the hiring of an Interim Chief Compliance Officer.
- Outlook: Management expects to continue using the credit facility for working capital and acquisitions once the forbearance agreement is resolved. They believe current cash balances and operating cash flows are sufficient for the next 12 months.
Investor Verification Checklist
- Forbearance Status: Verify the status of the forbearance agreement with the credit facility lenders and the timeline for resolving the "Technical Events of Default."
- Investigation Outcomes: Monitor developments in the DOJ and SEC investigations, as adverse outcomes could result in significant fines, penalties, or restitution.
- Restatement Impact: Review the full details of the restatement adjustments to understand the magnitude of prior revenue recognition errors and lease classification issues.
- Internal Control Remediation: Assess the progress of the remediation plan for material weaknesses in internal controls over financial reporting.
- Liquidity Position: Confirm that the company maintains the required $100 million unrestricted cash balance as a condition of the forbearance agreement.
- Legal Exposure: Track the status of the securities class action and derivative lawsuits for potential settlement costs or judgments.